Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04566328 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 649 to 647v29
  2. Site details revised at 1 of 649 sitesv28
  3. Trial sites expanded: 600 → 649 locationsv27
  4. 7 versions Re-verified since Oct 28, 2025, no change to tracked fieldsv20-v26
  5. Site details revised at 1 of 600 sitesv19
Show 17 earlier versionsHide 17 earlier versions
  1. Study sites: 460 to 600v18
  2. Re-verified, no change to tracked fieldsv17
  3. Start date: Oct 27, 2020 to Feb 24, 2021v16
  4. Re-verified, no change to tracked fieldsv15
  5. Study sites: 458 to 460v14
  6. Study sites: 439 to 458v13
  7. Study sites: 434 to 439v12
  8. Study sites: 430 to 434v11
  9. Study sites revised (430)v10
  10. Study sites: 424 to 430v9
  11. Study sites: 382 to 424v8
  12. Study sites: 376 to 382v7
  13. Study sites: 345 to 376v6
  14. Study sites: 52 to 345v5
  15. Study sites: 1 to 52v4
  16. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 28, 2020 to Oct 27, 2020
    v3
  17. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Trial Details
NCT Number NCT04566328
Lead Sponsor ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Related terms Multiple Myeloma
Enrollment 1,450 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov